WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cellect Biotechnology | August 10, 2020
Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that it has significantly strengthened its Intellectual Property (IP) portfolio as European Patent Application No. 14851547.1 has been granted. The patent will be set to expire in October 7, 2034, subject to patent term adjustment or extension."This is a pivotal event for Cellect and perhaps one of the most crucial developments for us&nb...
The Lynx Group | August 14, 2020
The Lynx Group (TLG) has acquired Upstream Partners in an effort to create a dynamic division catering directly to the pharmaceutical and biotech space. The ability to leverage the deep experiences and broad networks of both companies with external healthcare decision-makers and influencers together, allows the new division of TLG to provide pharmaceutical and biotech clients with thorough, market-informed perspectives needed throughout a product's life cycle. These insights are invaluable f...
Moleculin | September 29, 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2. Independent laboratory testing of the new drug candidate, called "WP1096," has now repea...
PR Newswire | August 21, 2020
CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all kno...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE